Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-α in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile
| Autor: | Sebastiano Buti, Domenico Potenzoni, Augusto Vaglio, Umberto Maggiore, Federico Alberici, Carlo Buzio, Rodolfo Passalacqua |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Alpha interferon Renal cell carcinoma Internal medicine medicine Carcinoma Humans Carcinoma Renal Cell Interferon alfa Neoplasm Staging Retrospective Studies Immunotherapy Interferon-α Interleukin-2 Prognostic factor business.industry Interferon-alpha Cancer General Medicine Prognosis medicine.disease Combined Modality Therapy Kidney Neoplasms Treatment Outcome Immunology business Kidney cancer medicine.drug Kidney disease |
| Zdroj: | Oncology. 76:69-76 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000178810 |
| Popis: | Objective: We report the results obtained using an original immunotherapy schedule featuring chronically administered low-dose interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with metastatic renal cell carcinoma (mRCC), and we assess treatment efficacy according to the patients’ prognostic profiles. Methods: 138 consecutive patients were enrolled, and received IL-2 (1 million IU/m2) subcutaneously twice daily on days 1 and 2, and once daily on days 3–5 of each week, and IFN-α (1.8 million IU/m2) intramuscularly once daily on days 3 and 5. Each cycle consisted of 4 consecutive weeks and was repeated indefinitely at 4-month intervals regardless of response. The patients’ baseline risk profile was assessed using Negrier’s stratification system. Results: The overall response rate was 10.9% (95% CI 6.7–17.2), and median overall survival was 19.6 months (95% CI 14.2–28.2). Treatment-related toxicity was mostly WHO grade 2 or below. Survival in the low-, intermediate- and high-risk groups was significantly different (p for trend Conclusion: Chronically administered low-dose IL-2 and IFN-α may be a safe and effective option for low-risk mRCC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|